Jennifer Jarrett - 25 Sep 2026 Form 4 Insider Report for Damora Therapeutics, Inc. (DMRA)

Reporting relationship: Director, President and CEO, Director
Issuer ticker: DMRA
Reported as of: 25 Sep 2026
Net transaction value: +$252,875
SEC form: 4
Accepted by SEC: 28 Sep 2026, 07:00:04 UTC
Prior SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Garrett Winslow, Attorney-in-Fact

Key filing fact

Jennifer Jarrett filed Form 4 for Damora Therapeutics, Inc. (DMRA) on 28 Sep 2026.

Key facts

This page summarizes Jennifer Jarrett's Form 4 filing for Damora Therapeutics, Inc. (DMRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Sep 2026, 07:00.

Change

Previous filing in this sequence was filed on 22 Jun 2026.
Current net transaction value: +$252,875.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001671311 Primary reporting owner

Jarrett Jennifer

Relationship: Director, President and CEO, Director
Address: C/O DAMORA THERAPEUTICS, INC., 100 FIFTH AVENUE, SUITE 700, WALTHAM
Signature: /s/ Garrett Winslow, Attorney-in-Fact
Signature date: 28 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMRA transaction

Ordinary Shares

Purchase

Transaction value: $252,875
Shares: +12,500
Change %: +2.5%
Price: $20.23
Shares after: 512,500
Date: 25 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares purchased on the open market at prevailing market prices using personal funds.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.10 to $20.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F3

Includes 500,000 restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one ordinary share of the Issuer.